IFN-gamma ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	2

65. Primary immunodeficiency

---

Clinical trials : 500 /  Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05463133 (ClinicalTrials.gov)	July 8, 2022	15/7/2022	Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists	Phase I/II Study Using Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists	Chronic Granulomatous Disease	Drug: Sirolimus;Drug: Cyclophosphamide;Drug: Alemtuzumab;Drug: Busulfan;Biological: Pheripheral blood stem cells;Drug: Emapalumab-Izsg;Drug: Tociluzumab;Drug: Total Body Irradiation	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	4 Years	65 Years	All	50	Phase 1/Phase 2	United States
2	NCT01147042 (ClinicalTrials.gov)	May 18, 2010	17/6/2010	Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease	Assessment of the Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease	IFN-Gamma Therapy;CGD Gene Mutation;CGD Response to IFNg;CGD - Chronic Granulomatous Disease;Immunodeficiency Disease	Drug: IFN-gamma	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Terminated	N/A	N/A	All	2	Phase 4	United States